NetworkNewsBreaks

TuesdayOct 27, 2020 1:52 pm

NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Positive Results in Ongoing Phase 2 Combination Therapy Trial with MS1819

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company, recently announced positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). In the primary efficacy analysis, patients receiving MS1819 in combination with PERT therapy achieved a clinically meaningful improvement in the coefficient of fat absorption (“CFA”) at each of the three dose levels. No adverse safety events were reported and, additionally, patients showed improvements in the key secondary endpoints, including body weight, stool consistency and reductions in the number of bowel…

Continue Reading

TuesdayOct 27, 2020 1:09 pm

NetworkNewsBreaks – Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) Featured on Critical Minerals Segment of ‘Mornings with Maria’

Standard Lithium (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF), an innovative technology and lithium project development company, today announced that its CEO Robert Mintak was a featured guest on Fox Business Network’s “Mornings with Maria” with anchor Maria Bartiromo. During the segment, which aired on Monday October 26, 2020, the two discussed the need for the lithium industry to adjust the critical minerals supply chain from China to the United States. Mintak summarized the progress being made at Standard Lithium’s Arkansas project. He highlighted the fact that currently the only lithium extraction that is actively underway in the U.S. is at…

Continue Reading

TuesdayOct 27, 2020 12:31 pm

NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) CEO Provides Company Updates on Exclusive NNW Audio Interview

Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was featured in a recent NetworkNewsWire (“NNW”) audio interview. During the interview, Schwartz provided updates on the company’s subsidiaries, noted recent company milestones and outlined near-term goals. POAI, a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has four wholly owned subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Schwartz focused the discussion on these companies, offering brief insight into the operations of Skyline Medical and noting that the purpose of TumorGenesis was to develop a lab media to replace rats and mice in the scientific industries…

Continue Reading

TuesdayOct 27, 2020 12:15 pm

NetworkNewsBreaks – Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) Advances on Goal to Become ‘Nevada’s Next Operating Gold Mine’

Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) today announced it has closed the transaction with Barrick Gold Corporation (NYSE: GOLD) (TSX: ABX) and Augusta Group (“ Augusta ”). According to the update, the company has now added 1,500 acres of ground adjoining its Bullfrog Gold Project (“Project”), strengthened its board of directors and management team, including the addition of Maryse Belanger as president and CEO, and completed a C$22 million private placement financing (together, the “Transaction”). “We are extremely excited about the upside potential of the combined land packages,” Belanger said in the press release. “We are expediting…

Continue Reading

TuesdayOct 27, 2020 11:49 am

NetworkNewsBreaks – Brain Scientific Inc. (BRSF) Announces Partnership with Dalmore Group for Upcoming Offering

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, is partnering with the Dalmore Group, a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”), for a regulation A+ offering. Based in New York, the Dalmore Group has an active presence in the Reg A+ equity funding space and is one of the most active broker-dealers in the world for Regulation A+ offerings; the company has served as broker-dealer on more than 50 such offerings in the past year. Brain Scientific recently unveiled its exclusive NeuroCap(TM) device, a next-generation, 19-channel, hospital-grade disposable…

Continue Reading

TuesdayOct 27, 2020 11:06 am

NetworkNewsBreaks – DGTL Holdings Inc. (TSXV: DGTL) Unveils Channel Partnership Program to Market Subsidiary’s Products

DGTL Holdings (TSXV: DGTL), on behalf of its wholly owned subsidiary Hashoff LLC, has announced a new channel partnership program. Initially launched in July 2020, the new program is designed to market Hashoff's products to top-ranked digital media publishers who actively sell enterprise-level Content as a Service (“CaaS”) and social media software solutions to Fortune 100 brands around the world. Hashoff is an enterprise-level, self-service CaaS, which is based on proprietary artificial intelligence and machine learning (“AI-ML”) technology. Through the channel partnership program, Hashoff has added new accounts and revenue streams within underserved growth categories. The new program is now live in…

Continue Reading

TuesdayOct 27, 2020 10:33 am

NetworkNewsBreaks – Cannabis Global Inc. (CBGL) Announces Research Partnership to Develop Cannabinoid Infusion Techniques

Cannabis Global (OTC: CBGL), a cannabinoid and hemp-extract, science-forward company developing infusion and delivery technologies, has formed a key research relationship with Marijuana Company of America Inc. (OTC: MCOA). MCOA joins the Project Varin research and development program, along with already existing partner Natural Plant Extract of California Inc. ("NPE"). The companies are collaborating on the development of new protocols and techniques for food and beverage cannabinoid infusion. Recently the program has created highly loaded cannabinoid nano units made from all-natural ingredients. These nano units will allow product formulators to create foods and beverages with clean labels and without bitter…

Continue Reading

TuesdayOct 27, 2020 10:13 am

NetworkNewsBreaks – Friendable Inc. (FDBL) to Bring Entertainment to Virtual Stage Through First Official Fan Pass Live Halloween Event

Friendable (OTC: FDBL), a mobile technology and marketing company engaging users through its proprietary mobile and desktop applications, today unveiled a new promotion for all active artists on the Fan Pass platform, offering them a paid promotion prior to any Halloween performances they schedule and broadcast through Fan Pass. As Halloween 2020 is disguised to look very different for most this year, Fan Pass intends to enhance the evening for both artists and their fans, bringing live entertainment to the virtual stage. “We think this Halloween Live promotion is a real win-win for both the artists and their fans,” said…

Continue Reading

TuesdayOct 27, 2020 9:41 am

NetworkNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) to Announce Q3 2020 Results, Host Conference Call

Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and health-care platform, will release financial results for the third quarter ended September 30, 2020, after market close on Monday, October 26, 2020. According to the update, Trxade management will host a conference call to discuss the results at 5:00 p.m. Eastern Time on Monday, October 26, 2020. The call will conclude with Q&A from participants. Interested parties may join the call by dialing 1-877-425-9470 (U.S.) or 1-201-389-0878 (International) and entering conference ID: 13711397. To register for the event, visit the following webcast link: https://nnw.fm/r6qQq. Attendees are asked to dial in…

Continue Reading

MondayOct 26, 2020 12:51 pm

NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Eric Chapdelaine to Senior Manufacturing Team

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the promotion of Eric Chapdelaine to vice president of manufacturing. According to the update, Chapdelaine’s promotion is a result of the company’s achievement of key manufacturing milestones to support upcoming clinical trials of its lead drug candidate — GPX-001 (quaratusugene ozeplasmid). “The appointment of Eric to our senior team is a hallmark of our manufacturing achievements and highlights the progress we have made in scaling up our manufacturing to commercial scale, which will further supply our upcoming clinical trials,” said Michael…

Continue Reading